Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

摘要: (1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that designed to stimulate the patient's T-cells recognize and attack prostate cancer cells express prostatic acid phosphatase (PAP) antigen. (2) demonstrated a survival benefit in men with advanced androgen-independent (AIPC), although this preliminary finding requires confirmation larger trials. (3) Mild moderate myalgia, chills, fever, tremor are most commonly reported adverse events for patients receiving sipuleucel-T. These generally resolve quickly. (4) More studies needed evaluate sipuleucel-T earlier stages of combination conventional therapies.